Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-010"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-010"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0112
lpv:speaker	lp:Giuseppe Nistico'2
lpv:spokenAs	substitute; Committee on Industry, External Trade, Research and Energy (2002-01-17--2004-07-19)3 member; EPP-ED (1999-07-20--2004-07-19)3 unknown; Forza Italia (1999-07-20--2004-07-19)3 member; Delegation to the EU-Bulgaria Joint Parliamentary Committee (2002-10-21--2004-07-19)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3
lpv:translated text	". Mr President, I would like to start by thanking Mrs Müller and Mrs Grossetête for their work and for the goodwill they have displayed in working on reports on subjects which are certainly difficult and complex for all but the experts. The primary objective of all the institutions – Parliament, the Commission and the Member States – should be to introduce, at last, new legislation which is better than the previous legislation and which will provide all patients, including those suffering from serious, terminal illnesses, with as rapid access as possible to new medicinal products which are more powerful and easier to tolerate than existing medicinal products, to alleviate their suffering and extend and improve their quality of life. In the short space of time available to me, I will focus on just a few points. As regards the European Agency for the Evaluation of Medicinal Products, I am completely opposed to the proposal regarding the membership of the management board. A management board such as that proposed by the Commission, and by the rapporteur, Mrs Müller, too, would certainly be doomed to failure. The presence on the management board of members representing the institutions and, in addition, of members with conflicting interests – such as industry, patients and insurance companies – would only lead to confusion, wasted time and major disputes. The second point I would like to make concerns the centralised procedure, where evaluation is carried out by the European Agency. The concept of ‘new medicinal product’ needs to be better defined, Commissioner. What is meant by the term ‘new medicinal product’? Does it refer to a medicinal product which has the same structure as existing medicinal products but with a very small change, or does it actually refer to medicinal products with a new chemical structure? I hope that you and the Council will think again on this matter."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph